A district court ruled in favor of Avanir Pharmaceuticals Inc. (Nasdaq: AVNR) in its patent infringement suit against Par Pharmaceuticals and Impax Laboratories. The stock price leaped $1.56 to close at $4.98.
Avanir Wins Patent Battle
April 30, 2014 at 17:34 PM EDT
